Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 235 от 240

Active (not recruiting) Phase 3

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Начало: 27.03.2017 Край: 31.12.2026 Възраст: 18–130 г.

Argentina, Austria, Brazil +20 AstraZeneca NCT03043872

Active (not recruiting)

Ovarian Tissue Cryopreservation in Children

Cancer

The Institutional Review Board (IRB) protocol is being designed to offer ovarian tissue cryopreservation to female pediatric patients (birth-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential. Because this procedure is currently considered experimental, the establishment of an IRB protocol under which this opportunity can be offered is needed.

Начало: 16.03.2017 Край: 22.01.2040 Възраст: до 17 г.

United States Mayo Clinic NCT02646384

Active (not recruiting)

Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Prostate Carcinoma

The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy. Investigators would like to understand how these treatments control the prostate cancer and look at their short and long term treatment related side effects. The dose of radiation for HDR brachytherapy for this study has been changed since the study started. Other studies using the dose of radiation for HDR brachytherapy that was originally chosen for this study (Arm 2) found that this dose of radiation may be linked to a greater chance of the cancer coming back in the prostate. Therefore since March 2020, for new participants entering the study, a new HDR brachytherapy arm with a higher amount of radiation given over two doses will be tested in this study

Начало: 06.03.2017 Край: 30.10.2029 Възраст: от 18 г.

Canada Canadian Cancer Trials Group NCT02960087

Active (not recruiting)

Zirconia Implants for Replacement of a Single Tooth

Partial-edentulism

First, the surgical insertion of a ceramic (zirconia) dental implant will be performed in a single-tooth gap according to current state-of-the-art protocols. After a 3-months healing phase, a ceramic tooth replacement (a.k.a. implant crown) will be screw-retained on the implant and will be ready for full chewing, aesthetic and speech function.

Начало: 01.03.2017 Край: 28.02.2030 Възраст: от 18 г.

Switzerland University of Bern NCT04695899

Active (not recruiting)

Persona Partial Knee Clinical Outcomes Study

Osteoarthritis Avascular Necrosis Traumatic Arthritis Conditional Tibial Condyle or Plateau Fractures +1

The primary objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available Persona Partial Knee System.

Начало: 08.02.2017 Край: 01.09.2030 Възраст: от 18 г.

Austria, Belgium, France +7 Zimmer Biomet NCT03034811

Active (not recruiting)

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

Colorectal Cancer Metastatic

The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.

Начало: 27.01.2017 Край: 27.01.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT03038568

Active (not recruiting) Phase 2

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Breast Adenocarcinoma Estrogen Receptor- Negative Breast Cancer Estrogen Receptor-positive Breast Cancer HER2/Neu Negative +9

This study is a 2-cohort, open-label, multicenter, phase 2 study of a short course of immunotherapy consisting of sequential decitabine followed by pembrolizumab administered prior to a standard neoadjuvant chemotherapy regimen for patients with locally advanced HER2-negative breast cancer. The primary efficacy objective is to determine if the immunotherapy increases the presence and percentage of tumor and/or stromal area of infiltrating lymphocytes prior to initiation of standard neoadjuvant chemotherapy. At enrollment, patients will be assigned to one of 2 cohorts based on hormone receptor status. * Cohort A - patients with HER2-negative, hormone receptor-negative breast cancer (defined as both ER and PgR with \< 10% positive staining on IHC) Note: before beginning standard neoadjuvant chemotherapy, patients in Cohort A may be reassigned to Cohort A2 to receive extended pembrolizumab as part of new standard neoadjuvant and postoperative adjuvant therapy. * Cohort B - patients with HER2-negative, hormone receptor-positive breast cancer (defined as either ER or PgR with ≥ 10% positive staining on IHC)

Начало: 24.01.2017 Край: 31.03.2027 Възраст: от 18 г.

United States Virginia Commonwealth University NCT02957968

Active (not recruiting) Phase 3

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Breast Carcinoma In Situ Invasive Breast Carcinoma Stage I Breast Cancer AJCC v7 Stage II Breast Cancer AJCC v6 and v7 +2

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Начало: 18.01.2017 Край: 31.05.2026 Възраст: от 18 г.

Canada, Puerto Rico, United States National Cancer Institute (NCI) NCT02954874

Active (not recruiting)

The Developmental Origins of Suicide Mortality

Suicide Mortality

Background: Suicide rates are rising. In 2013, it was the third leading cause of death in children ages 10-14. It was the second leading cause of death for ages 15-24. Many risk factors for suicide have been found. But it is hard to predict. Evidence is growing that some factors that may make people vulnerable to suicide can be identified before birth or in early childhood. Researchers want to study vulnerability to suicide. They want to look at different kinds of development. These include prenatal, social, behavioral, cognitive, and neurologic. They will do this by linking data from the United States Collaborate Perinatal Project (CPP) to the National Death Index (NDI). The CPP data are from about 50,000 children born to mothers who enrolled in the 1960s. The CPP observed and examined about 60,000 pregnancies. Then it followed the babies from when they were born through age 7. The CPP collected data on things like family and medical history, economic status, and behavior. The NDI has data on the date and cause of death. Objective: To link data from the CPP to the NDI in order to study certain precursors to suicide. Eligibility: Offspring born to women who enrolled in the CPP in 1959-1966 and known to be alive at age 7 (Note: at the start of this study around in 2016, the youngest of those still alive would be 50 and the oldest would be 57 years old). Design: Data on children from the CPP will be submitted electronically to the NDI. It will be encrypted and data from the NDI will be deidentified to protect confidentiality. It will then be merged with existing CPP data. Researchers will analyze the data. ...

Начало: 10.01.2017 Край: 13.07.2026

United States Eunice Kennedy Shriver National Institute of Child Heal NCT03027440

Active (not recruiting) Phase 1/2

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

Breast Cancer

This protocol is for patients with newly diagnosed breast cancer with an indication for post-operative radiotherapy after neo-adjuvant chemotherapy and surgery.

Начало: 19.12.2016 Край: 31.12.2026 Възраст: 19–99 г.

United States Weill Medical College of Cornell University NCT02917421

Active (not recruiting)

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

Ulcerative Colitis

The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.

Начало: 16.12.2016 Край: 11.03.2027 Възраст: от 18 г.

Austria, Canada, Czechia +6 Janssen Biotech, Inc. NCT02808780

Active (not recruiting)

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Hepatocellular Cancer

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Начало: 01.12.2016 Край: 01.02.2027 Възраст: от 18 г.

France, Germany, Italy +2 Target PharmaSolutions, Inc. NCT02954094

Active (not recruiting)

Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction

Transfemoral Amputees

The overall goal of this research is to determine the efficacy of new powered prosthetic devices for individuals with transfemoral amputations. The anticipation is that this will be a high-impact technological intervention with the potential to restore significant functionality to individuals with lower limb amputation and transform the field of lower limb prosthetics. The objective of the proposed clinical trial is to fully evaluate the biomechanical and energetic effects of using PKA prosthesis and quantify functional performance and quality of life changes.

Начало: 01.12.2016 Край: 01.12.2026 Възраст: 18–80 г.

United States Shirley Ryan AbilityLab NCT03204513

Active (not recruiting) Phase 1

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.

Начало: 18.11.2016 Край: 01.12.2026 Възраст: от 18 г.

United States Providence Health & Services NCT02812524

Active (not recruiting) Early Phase 1

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Triple-Negative Breast Carcinoma

This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.

Начало: 07.11.2016 Край: 30.04.2028 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT02744053

Active (not recruiting)

Investigation of Chronic Intestinal Ischemia

Chronic Mesenteric Ischemia

Patients suspected of chronic mesenteric ischemia caused by atherosclerosis or median arcuate ligament syndrome shall be investigated with trans mucosal and transserosal laser Doppler flowmeter and visible light spectroscopy.

Начало: 01.09.2016 Край: 01.12.2026

Norway Oslo University Hospital NCT02914912

Active (not recruiting) Phase 2

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Malignant Digestive System Neoplasm Metastatic Head and Neck Carcinoma Metastatic Kidney Carcinoma Metastatic Malignant Neoplasm in the Spine +9

This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal cord. Thermal ablation uses a laser to heat tumor tissue and helps to shrink the tumor by destroying tumor cells. Stereotactic radiosurgery delivers a large dose of radiation in a short time precisely to the tumor, sparing healthy surrounding tissue. Combining thermal ablation with stereotactic radiosurgery may be a better way to control cancer that has spread to the spine and is at risk for compressing the spinal cord.

Начало: 29.08.2016 Край: 28.10.2027 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT02713269

Active (not recruiting) Phase 3

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 Stage II Lung Non-Small Cell Cancer AJCC v7 Stage IIIA Lung Non-Small Cell Cancer AJCC v7

This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Начало: 22.07.2016 Край: 31.12.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT02595944

Active (not recruiting) Phase 2

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Craniopharyngioma

Craniopharyngioma is a rare brain tumor that affects both children and adults. It arises in a region of the brain near the pituitary gland, visual pathways, and central blood vessels. Patients often present with headache, loss of vision or delayed growth. In some instances they may present with imbalance of water and salts in the body. The treatment for craniopharyngioma may be radical surgery or a combination of surgery and radiation therapy. In some instances surgery is not required. If the tumor cannot be completely removed, radiation therapy may be required. In this study we will use the most advanced form of proton therapy which is called intensity-modulated proton therapy. This is a newer form of radiation therapy which has a number of advantages over older forms of proton therapy and conventional radiation therapy using x-rays. The main goal of this study is to learn if proton therapy will effectively treat patients with craniopharyngioma brain tumors and reduce side effects compared to more traditional forms of radiation therapy.

Начало: 22.06.2016 Край: 01.12.2028 Възраст: до 21 г.

United States St. Jude Children's Research Hospital NCT02792582

Active (not recruiting) Phase 2

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma Advanced Malignant Solid Neoplasm Hematopoietic and Lymphatic System Neoplasm Refractory Lymphoma +2

This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have a smoothened or patched 1 genetic mutation. Vismodegib is a type of medication called a hedgehog signaling pathway antagonist and works by blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells.

Начало: 20.06.2016 Край: 31.12.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT06357988

1 … 233 234 235 236 237 … 240